Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 308-309

  Strunk, Crawford J ^a   Platzbecker, Uwe ^b   Thiede, Christian ^b   Schaich, Markus ^b   Illmer, Thomas ^b   Kang, Zizhen ^a   Leahy, Patrick ^a   Li, Chunbiao ^a   Xie, Xiuyan ^a   Laughlin, Mary J ^a   Lazarus, Hillard M ^a   Gerson, Stanton L ^a   Bunting, Kevin D ^a   Ehninger, Gerhard ^b   Tse, William ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ONCOPROTEIN; ONCOPROTEIN AF1Q; PROTEIN KINASE FER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA WITH NORMAL CYTOGENETICS; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENE DUPLICATION; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM REPEAT;

ADOLESCENT; ADULT; BLOOD PROTEINS; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 65649120444     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21396     Document Type: Article

References (10)

1. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
2. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 1997;80:2205-2209.
3. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002;100:4372-4380. (Pubitemid 35434129)
4. Baldus CD, Thiede C, Soucek S, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 2006;24:790-797. (Pubitemid 46622046)
5. Tse W, Meshinchi S, Alonzo TA, et al. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 2004;104:3058-3063.
6. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 2005;23:9234-9242.
7. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006;108:3898-3905.
8. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-3261. (Pubitemid 35434129)
9. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-633.
10. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005;106:3740-3746.